Efficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial - PubMed
6 hours ago
- #Myasthenia Gravis
- #Randomized Trial
- #Pyridostigmine
- Pyridostigmine significantly improved Myasthenia Gravis symptoms (MGII score difference: 5.3) in a randomized trial.
- Secondary measures (QMG, MG-ADL, MG-QOL15r) also showed significant benefits for pyridostigmine over placebo.
- Cost-utility analysis indicated lower annual costs (€6,565) and improved quality-adjusted life years (0.106 QALYs) with pyridostigmine.
- The study provides Class I evidence for pyridostigmine's efficacy in anti-acetylcholine receptor-positive myasthenia gravis.